EFFICACY OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS FOR CARDIAC FUNCTION IN DIABETIC PATIENTS WITH ISCHEMIC HEART DISEASE  by Kitano, Daisuke et al.
Prevention
A1417
JACC March 17, 2015
Volume 65, Issue 10S
efficacy of DipeptiDyl peptiDase-4 inHibitoRs foR caRDiac function in Diabetic 
patients witH iscHeMic HeaRt Disease
Poster Contributions
Poster Hall B1
Saturday, March 14, 2015, 3:45 p.m.-4:30 p.m.
Session Title: Blood Pressure, Diabetes and Other Risk Factors
Abstract Category: 21.  Prevention: Clinical
Presentation Number: 1140-119
Authors: Daisuke Kitano, Tadateru Takayama, Rikitake Kogawa, Shunichi Yoda, Satoshi Kunimoto, Yuji Kasamaki, Takafumi Hiro, Atsushi 
Hirayama, Nihon University School of Medicine, Tokyo, Japan
background: I n patients with diabetes mellitus (DM), ischemic heart disease (IHD) is one of major prognostic factors. Also, DM is one 
of major risk factors in cardiovascular disease. It is reported that impaired glucose tolerance like postprandial hyperglycemia induces 
endothelial dysfunction and atherosclerosis. It has been documented that novel anti-diabetic agent dipeptidyl peptidase-4 (DPP-4) 
inhibitors have ameliorative effects for not only improving hyperglycemia and also suppressing cardiovascular events. We evaluated the 
clinical effects of DPP-4 inhibitors in DM patients with IHD.
Methods:  One hundred eighty diabetic patients with IHD (150 myocardial infarction and 30 angina pectoris) were enrolled. They were 
given 25 mg of alogliptin, 50 mg of sitagliptin or 50 mg of vildagliptin every day for 3 months, and we assessed casual glucose levels, 
hemoglobin A1c (HbA1c), 1,5-anhydro-D-glucitol (1,5-AG), N-terminal prohormone of brain natriuretic peptide (NT-proBNP) and ejection 
fraction (EF) by ultra sound at the starting of this study and 3 months after intervention.
Results:  After DPP-4 inhibitors administration, there were significant improvement in casual glucose (152.7 ± 38.8 to 149.6 ± 46.7 mg/dL, 
P < 0.001), HbA1c (6.7 ± 0.5 to 6.4 ± 0.5 %, P < 0.001), 1,5-AG (13.3 ± 7.8 to 15.4 ± 8.3 μg/mL, P < 0.001). Moreover in patients improved 
1,5-AG, NT-proBNP (253.6 ± 336.8 to 232.7 ± 366.9 pg/mL, P < 0.001), EF (63.8 ± 9.4 to 66.7 ± 10.1 %, P = 0.044) were significantly 
improved and there was a significant negative correlation between the change of 1,5-AG and the improvement of NT-proBNP (r = -0.421, P 
= 0.013).
conclusion:  In DM patients with IHD, DPP-4 inhibitors improved both HbA1c and 1,5-AG, moreover NT-proBNP and EF. The present 
study suggests that improvement of hyperglycemia due to DPP-4 inhibitors may affect cardiac function and better outcome. It needs to 
investigate long-term effects.
